Business of Commercializing Induced Pluripotent Stem Cells (iPSCs)-AN UPDATE


IPSCs-Induced Pluripotent Stem Cells are special kind of Pluripotent Stem Cells that can be directly generated from adult cells. Pluripotent stem cells are very important as they are vital in regenerative medicine. They can propagate indefinitely and give rise to any cell in the body like pancreatic, heart and liver cells. They are known as single source of cell which can be utilized to replace the lost or damaged cells during the course of recovery from a disease.

This iPSC technology was discovered by Shinya Yamanaka in his personal laboratory in the Kyoto region of Japan.

Back in 2006, when the discovery of Induced Pluripotent Stem Cells (iPSCs) happened; there were only two companies in the globe that were trading iPSC research products. This number in the following year (2007) crept to 7. Therefore with the early indication of demands, the competition increased and today the same has risen over 40. The market for iPSC research specific products is witnessing massive contest around the globe and thus pharma companies from all over are taking keen interest on the subject; making whopping investments.

Mentioned below is the year-on-year record of the commercializing Induced Pluripotent Stem Cells business.

 year-on-year record of the commercializing Induced Pluripotent Stem Cells business


Currently, there are 26 clinical studies involving creation and evaluation of iPSC lines for clinical purposes.


Most recent advancements in Commercializing of iPSCs-AN UPDATE:

August, 2014-

The most-talked about dispute over patent occurs between two groups of the medical world: Drs. Yamanaka and Takahashi and a pharma group known as the “BioGatekeeper”. This fight over patent is still ongoing; if successful in cancelling the patent it would bring in a spree of innovations leading to cost reduction in the iPSC industry. Several technologies, products and therapies are expected to cost less if the cancellation takes place.

August, 2013-

This was the first time when a clinical research was carried on transplant of iPSCs into humans. It was performed by Dr. Masayo Takahashi at RIKEN Center in Japan where with the help of macular degeneration he studies the safety measures of iPSC-derived cell sheets in patients.

July, 2013-

CDI-Cellular Dynamics International turns global leader as a producer of human iPSCs on the basis of industrial quantities. This happens as the company raises a whopping $43 million through an (IPO) initial public offering.

March, 2013-

California Institute of Regenerative Medicines (CIRM) grants multi-million dollars to Coriell Institute of Medical Research and Cellular Dynamics International (CDI). This grant was allotted to create iPSC lines from more than 3,000 healthy and diseased donors. Once completed; this will make the world’s largest human iPSC bank.

In the last couple of years, there have been great advances in the field of iPSC clinical research works, functions like applications, differentiating technologies and production process have picked up pace. The concept of bio-banking is going through new improvements on a regular basis; hence a lot more is expected to happen in the iPSC industry in the near future.

So, keep an eye to gain.